In summary, we provide initial real-world evidence of reduced alcohol consumption in people with obesity taking Semaglutide or Tirzepatide medications, suggesting potential efficacy for treatment in AUD comorbid with obesity. Note: Beyond what is publicly available today, several studies from established research groups showing substantial anti-addictive effects have been submitted to journals and will be published in mid-2024
case-by-case assessment) Severe uncontrolled depression, anxiety, or eating disorders (risk of worsening) Pregnancy or intent to become pregnant (GLP-1 safety in pregnancy not established
Bouzat P, Sala N, Suys T, Zerlauth JB, Marques-Vidal P, Feihl F, et al
He will also review your medical history and perform a physical exam to determine your eligibility for Semaglutide
The results of the EVOKE trials suggest: Timing matters: GLP-1s may be more effective in prevention or very early disease